147 related articles for article (PubMed ID: 23225192)
1. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
Forster M; Pertile P
Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based decision-making 3: Health technology assessment.
O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis.
Leelahavarong P
J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
[TBL] [Abstract][Full Text] [Related]
4. An introduction to the methods of cost-effectiveness analysis.
Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
[TBL] [Abstract][Full Text] [Related]
5. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
6. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
[TBL] [Abstract][Full Text] [Related]
7. Expected value of information and decision making in HTA.
Eckermann S; Willan AR
Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
[TBL] [Abstract][Full Text] [Related]
8. Presentation of economic evaluation results.
Chaikledkaew U
J Med Assoc Thai; 2014 May; 97 Suppl 5():S72-80. PubMed ID: 24964702
[TBL] [Abstract][Full Text] [Related]
9. Approaches for economic evaluations of health care technologies.
Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
[TBL] [Abstract][Full Text] [Related]
10. Value of research and value of development in early assessments of new medical technologies.
Retèl VP; Grutters JP; van Harten WH; Joore MA
Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment and primary data collection for reducing uncertainty in decision making.
Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
[TBL] [Abstract][Full Text] [Related]
12. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
13. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
14. A Conceptual Framework for Life-Cycle Health Technology Assessment.
Kirwin E; Round J; Bond K; McCabe C
Value Health; 2022 Jul; 25(7):1116-1123. PubMed ID: 35779939
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?
Tarride JE; McCarron CE; Lim M; Bowen JM; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
Int J Technol Assess Health Care; 2008; 24(4):437-44. PubMed ID: 18828938
[TBL] [Abstract][Full Text] [Related]
16. Capacity constraints and cost-effectiveness: a discrete event simulation for drug-eluting stents.
Jahn B; Pfeiffer KP; Theurl E; Tarride JE; Goeree R
Med Decis Making; 2010; 30(1):16-28. PubMed ID: 19789389
[TBL] [Abstract][Full Text] [Related]
17. Health technology assessment for radiologists: basic principles and evaluation framework.
Lim ME; O'Reilly D; Tarride JE; Burke N; Ferrusi IL; Campbell K; Goeree R
J Am Coll Radiol; 2009 May; 6(5):299-306. PubMed ID: 19394570
[TBL] [Abstract][Full Text] [Related]
18. Defining the scope of health technology assessment and types of health economic evaluation.
Tanvejsilp P; Ngorsuraches S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S10-6. PubMed ID: 24964694
[TBL] [Abstract][Full Text] [Related]
19. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Grimm SE; Strong M; Brennan A; Wailoo AJ
Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
[TBL] [Abstract][Full Text] [Related]
20. Incorporating option values into the economic evaluation of health care technologies.
Palmer S; Smith PC
J Health Econ; 2000 Sep; 19(5):755-66. PubMed ID: 11184803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
